MX2024000050A - Sistemas de deposito de semaglutida y uso de estos. - Google Patents
Sistemas de deposito de semaglutida y uso de estos.Info
- Publication number
- MX2024000050A MX2024000050A MX2024000050A MX2024000050A MX2024000050A MX 2024000050 A MX2024000050 A MX 2024000050A MX 2024000050 A MX2024000050 A MX 2024000050A MX 2024000050 A MX2024000050 A MX 2024000050A MX 2024000050 A MX2024000050 A MX 2024000050A
- Authority
- MX
- Mexico
- Prior art keywords
- semaglutide
- pharmaceutical compositions
- parenteral pharmaceutical
- present
- deposit systems
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title abstract 2
- 229950011186 semaglutide Drugs 0.000 title abstract 2
- 108010060325 semaglutide Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218405P | 2021-07-05 | 2021-07-05 | |
| US17/534,533 US11865213B2 (en) | 2021-07-05 | 2021-11-24 | Semaglutide depot systems and use thereof |
| PCT/IL2022/050708 WO2023281495A1 (en) | 2021-07-05 | 2022-07-04 | Semaglutide depot systems and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000050A true MX2024000050A (es) | 2024-03-08 |
Family
ID=84801375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000050A MX2024000050A (es) | 2021-07-05 | 2022-07-04 | Sistemas de deposito de semaglutida y uso de estos. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11865213B2 (https=) |
| EP (1) | EP4366759A4 (https=) |
| JP (1) | JP2024526279A (https=) |
| AU (1) | AU2022308705A1 (https=) |
| CA (1) | CA3220567A1 (https=) |
| IL (1) | IL309789A (https=) |
| MX (1) | MX2024000050A (https=) |
| WO (1) | WO2023281495A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| NL2036269B1 (en) | 2023-11-14 | 2025-05-23 | Nanomi B V | Peptide microparticle compositions and related methods |
| KR102930984B1 (ko) * | 2024-01-29 | 2026-02-25 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2025229403A1 (en) * | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| CN121015560B (zh) * | 2025-10-30 | 2026-01-30 | 上海银诺医药技术有限公司 | 依苏帕格鲁肽α纳米冻干胶束及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021531A2 (en) * | 2006-08-17 | 2008-02-21 | University Of Massachusetts | Stabilized emulsions, methods of preparation, and related reduced fat foods |
| TWI362947B (en) * | 2007-03-08 | 2012-05-01 | Univ Kaohsiung Medical | Controlled release pharmaceutical composition and manufacture method thereof |
| HUE060304T2 (hu) | 2010-01-04 | 2023-02-28 | Mapi Pharma Ltd | Glatiramer acetátot tartalmazó depó rendszer |
| EP2866825B1 (en) * | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| BR112016022550B1 (pt) * | 2014-03-31 | 2023-03-28 | Pharmathen S.A | Processo para a preparação de microesferas de plga de acetato de octreotida |
| CN105963257B (zh) * | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| CN105963258B (zh) * | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | 一种缓释微粒的制备方法 |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CA3040906A1 (en) * | 2016-10-20 | 2018-04-26 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
| US20190380967A1 (en) | 2017-01-23 | 2019-12-19 | Savior Lifetec Corporation | Preparation of microparticles of an active ingredient |
| KR102047983B1 (ko) | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
| CN110101846B (zh) | 2018-02-01 | 2022-09-23 | 齐鲁制药有限公司 | 一种低突释率的索玛鲁肽微球及其制备方法 |
| US20210162013A1 (en) | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| US20220183964A1 (en) | 2019-04-11 | 2022-06-16 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled, sustained release of therapeutic agents |
| JP7336813B2 (ja) | 2019-07-29 | 2023-09-01 | ペプトロン インコーポレイテッド | レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物 |
| CN113018277B (zh) * | 2019-12-25 | 2023-10-31 | 丽珠医药集团股份有限公司 | 注射用缓释制剂及其制备方法 |
| CN115484935A (zh) | 2020-02-14 | 2022-12-16 | G2G生物公司 | 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物 |
| WO2022003662A1 (en) * | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
-
2021
- 2021-11-24 US US17/534,533 patent/US11865213B2/en active Active
-
2022
- 2022-07-04 JP JP2023581040A patent/JP2024526279A/ja active Pending
- 2022-07-04 IL IL309789A patent/IL309789A/en unknown
- 2022-07-04 WO PCT/IL2022/050708 patent/WO2023281495A1/en not_active Ceased
- 2022-07-04 AU AU2022308705A patent/AU2022308705A1/en active Pending
- 2022-07-04 MX MX2024000050A patent/MX2024000050A/es unknown
- 2022-07-04 EP EP22835557.4A patent/EP4366759A4/en active Pending
- 2022-07-04 CA CA3220567A patent/CA3220567A1/en active Pending
-
2023
- 2023-12-19 US US18/544,721 patent/US20240148653A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL309789A (en) | 2024-02-01 |
| JP2024526279A (ja) | 2024-07-17 |
| CA3220567A1 (en) | 2023-01-12 |
| WO2023281495A1 (en) | 2023-01-12 |
| US20240148653A1 (en) | 2024-05-09 |
| EP4366759A1 (en) | 2024-05-15 |
| US20230014750A1 (en) | 2023-01-19 |
| US11865213B2 (en) | 2024-01-09 |
| EP4366759A4 (en) | 2025-04-09 |
| AU2022308705A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000050A (es) | Sistemas de deposito de semaglutida y uso de estos. | |
| CL2019001674A1 (es) | Inhibidores de imidazopirazina de tirosina quinasa de bruton. | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| UY30986A1 (es) | Derivados fluorinados de deferiprona | |
| CR20220491A (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| ECSP22020159A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
| PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
| ECSP099723A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer | |
| PA8589701A1 (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
| UY32622A (es) | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) | |
| UY29503A1 (es) | Derivados de amida sustituida y metodos de uso | |
| CR11100A (es) | Uso de inhibidores de piridopirimidinona de p13k-alfa en el tratamiento del cancer | |
| AR062402A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel | |
| CL2020001090A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas. | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| MX2019013308A (es) | Composiciones y compuestos terapeuticos, y metodos para su uso. | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| CL2025002808A1 (es) | Compuestos derivados de acilsulfonamida inhibidores de kat6a y uso para tratar cáncer. | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| PE20221595A1 (es) | Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares |